Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study by Amgen evaluated the safety and efficacy of CCX354-C in rheumatoid arthritis patients partially responsive to methotrexate; the trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CCX354-C

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED